Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
1.770
+0.120 (7.27%)
Sep 5, 2025, 4:00 PM - Market closed

Company Description

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.

The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.

The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.

It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.

In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea.

The company is headquartered in San Francisco, California.

Jaguar Health, Inc.
Jaguar Health logo
CountryUnited States
Founded2013
IndustryBiotechnology
SectorHealthcare
Employees49
CEOLisa Conte

Contact Details

Address:
200 Pine Street, Suite 400
San Francisco, California 94104
United States
Phone415 371 8300
Websitejaguar.health

Stock Details

Ticker SymbolJAGX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001585608
CUSIP Number47010C888
ISIN NumberUS47010C8881
SIC Code2834

Key Executives

NamePosition
Lisa A. ConteFounder, Chief Executive Officer, President and Director
Dr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer and Chair of Scientific Advisory Board
Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer and General Counsel
Dr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
Carol R. Lizak M.B.A.Chief Financial Officer
Peter HodgeSenior Director of Investor Relations, Business Development and Special Events
Dr. Karen J. Brunke Ph.D.Executive Vice President of Corporate and Business Development
David Sesin Ph.D.Chief Manufacturing Officer
Ian H. Wendt M.B.A.Chief Commercial Officer
Dr. Massimo Radaelli M.B.A., Ph.D.President of Jaguar International

Latest SEC Filings

DateTypeTitle
Aug 29, 2025SCHEDULE 13GFiling
Aug 19, 20258-KCurrent Report
Aug 14, 2025SCHEDULE 13G/AFiling
Aug 14, 20258-KCurrent Report
Aug 14, 2025424B5Filing
Aug 14, 202510-QQuarterly Report
Aug 6, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 30, 2025EFFECTNotice of Effectiveness
Jul 30, 2025424B3Prospectus
Jul 28, 2025UPLOADFiling